Revenue
2019
2020
2021
2022
2023
2024
2025
Goldenwell Biotech, Inc. (GWLL)
Price$0.7000Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $55 | $139 | $2,340 | $47,800 | $15,967 | $0 | $0 |
| Gross profit | $12 | $64 | $666 | $25,186 | $8,388 | $0 | $0 |
| Gross margin | 21.82% | 46.04% | 28.46% | 52.69% | 52.53% | — | — |
| Operating expenses | $113,338 | $123,162 | $116,492 | $1.0M | $126,655 | $6,368 | $2,601 |
| Operating income | −$113,326 | −$123,098 | −$115,826 | −$985,105 | −$118,267 | — | — |
| Operating margin | −206,047.27% | −88,559.71% | −4,949.83% | −2,060.89% | −740.70% | — | — |
| EBITDA | −$288,071 | −$123,098 | −$115,826 | −$985,105 | — | — | — |
| EBITDA margin | −523,765.45% | −88,559.71% | −4,949.83% | −2,060.89% | — | — | — |
| Net income | −$296,471 | −$131,498 | −$117,361 | −$985,097 | −$116,981 | −$6,324 | −$2,311 |
| Net profit margin | −539,038.18% | −94,602.88% | −5,015.43% | −2,060.87% | −732.64% | — | — |
| Basic EPSper basic share | -$0.00 | -$0.00 | $0.00 | -$0.01 | $0.00 | $0.00 | $0.00 |
| Diluted EPSper diluted share | $0.00 | $0.00 | $0.00 | -$0.01 | $0.00 | $0.00 | $0.00 |
Owners
Reported shareholders